Genomics giant Illumina blueprints new Euro HQ/science center in Cambridge, UK

Illumina CFO Marc Stapley

The gene-sequencing pioneers at Illumina ($ILMN) are planning to build a major new science center and European headquarters in the U.K.'s growing biotech hub in Cambridge. Illumina signed a lease on a 155,000-square-foot facility, designed to grow another 70,000 square feet as needed for future expansion.

Illumina struck a deal to build the new HQ with BioMed Realty, which is developing a campus next door to Cambridge University. Cambridge is also slated to become home to AstraZeneca's ($AZN) new complex, a passion project for CEO Pascal Soriot, who's determined to turn around the one-time pharma laggard.

 "This new state-of-the-art European Headquarters will provide enhanced collaboration opportunities for our growing employee base, which is so foundational to Illumina's innovation and success," says Marc Stapley, the CFO for Illumina.

Illumina knows the area well. The company's Solexa deal added operations in Cambridge and Illumina later added BlueGnome's arrays for genetic screening a few years ago.

"Illumina and BioMed Realty's commitment to building a new state-of-the art facility in Cambridge is great news for our area," said George Freeman, the undersecretary of state for life sciences. "This is a strong endorsement of the UK's Life Science Industrial Strategy and leadership in driving forward better treatments for people with cancers and rare diseases."

- here's the release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.

The series A gives ex-Roche VP George Garibaldi a chance to realize the potential of assets that fell by the wayside at the Swiss pharma.